Filed・Approved
As of Mar. 31, 2017
Approved in SG
Filed in HK, MY
◎ARQ 197
Tivantinib
Oral
c-Met Inhibitor
Hepatocellular Cancer
Phase III
in JP
Licensed from
ArQule
Phase Iin JP
Phase IIin US
Phase II in US
Phase II in JP and
KR
Updated since Jan 24th,
2017 （Area, Stage, Filed, Approved, etc.）
◎
R&D Pipeline
Aplastic Anemia
PhaseII/III
in JP and KR
Phase II, Phase III
Central
Nervous
System
KW-6002
Istradefylline
Oral
Adenosine A
2A
Receptor Antagonist
Parkinson’s Disease
Phase III
in US, CA, EU and
others
Phase IIin JP
Phase II
in US, EU and
others
KHK4827
Brodalumab
Injection
Anti-IL-17 Receptor
A Fully Human
Antibody
Psoriasis
Phase III in KR
Nephrology
Area
In-House
Human Antibody-Producing Technology
Jointly Developed with
Ultragenyx in US and EU
X-linked
Hypophosphatemia (XLH)
in pediatric patients
Phase III in US, CA,
EU, AU, JP, KR
Tumor Induced
Osteomalacia(TIO)/Epider
mal Nevus Syndrome
(ENS)
Kirin-Amgen
◎ASKP1240
Bleselumab
Injection
Anti-CD40 Fully
Human Antibody
Organ Transplant
Rejection
In-House
Human Antibody-Producing Technology
Jointly Developed with Astellas
◎KRN23
burosumab
Injection
Anti-FGF23 Fully
Human Antibody
X-linked
Hypophosphatemia(XLH)
in adult patients
Phase III in US, CA,
EU, JP and KR
In-House
◎ＫＷ-6356
Oral
Adenosine A
2A
Receptor Antagonist
Parkinson’s Disease
In-House
Oncology
Jointly Developed with
AstraZeneca/MedImmune
Chronic Obstructive
Pulmonary Disease(COPD)
Phase III in JP
Eosinophilic Chronic
Rhinosinusitis (ECRS)
Phase II in JP
In-House
POTELLIGENT

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Human Antibody-Producing Technology
◎KHK4563
Benralizumab
Injection
Anti-IL-5 Receptor
Humanized Antibody
Asthma
Phase III in JP and
KR
In-House
POTELLIGENT

Immunology
/Allergy
◎KHK4083
Injection
Anti-OX40 Fully
Human Antibody
Ulcerative colitis
KW-0761
Mogamulizumab
Injection
Anti-CCR4
Humanized Antibody
Adult T-cell
Leukemia/Lymphoma
Ph
ase
II
in US, EU and
others
In-House
POTELLIGENT

Cutaneous T-cell
Lymphoma
Phase III
in US, EU, JP and
others
In-House
or
Licensed
Remarks
Licensed from
Reata
◎KHK7580
Evocalcet
Oral
Calcium Receptor
Agonist
Secondary
Hyperparathyroidism
PhaseIII
in JP
Li
cense
d
f
rom
Mitsubishi
Tanabe
Pharma
◎RTA 402
Bardoxolone Methyl
Oral
Antioxidant
Inflammation
Modulator
CKD in Patients with Type
2 Diabetes
PhaseII
in JP
Code Name
Generic Name
Formulation
Mechanism of Action
Indication
Stage
Kirin-Amgen
◎KRN23
burosumab
Injection
Anti-FGF23 Fully
Human Antibody
X-linked
Hypophosphatemia (XLH)
Filed in EU
In-House
Human Antibody-Producing
Technology
Jointly Developed with Ultragenyx
in US and EU
Filed in BN
Licensed from
NPS
Other
AMG531
Romiplostim
Injection
Thrombopoietin
Receptor Agonist
Idiopathic (Immune)
Thrombocytopenic
Purpura
Approved in TH
Licensed from
Solasia Pharma
Z-206
Mesalazine
Oral
pH Dependent
Controlled
Release Tablet
Ulcerative Colitis
(Additional Dosage and
Administration)
Filed in JP
Licensed from
Zeria Pharma
Jointly Developed with Zeria
Pharma
NDA holder is Zeria Pharma
Oncology
Granisetron
Patch
５-HT
3
Serotonin
Receptor Antagonist
Chemotherapy induced
Nausea and Vomiting
Filed in MY
Area
Code Name
Generic Name
Formulation
Mechanism of Action
Indication
Myelodysplastic Syndromes
Kirin-Amgen
KRN321
Darbepoetin Alfa
Injection
Long-Acting
Erythropoiesis
Stimulating Agent
Stage
In-House
or
Licensed
Remarks
Nephrology
Renal Anemia (on Dialysis)
NDA in preparation
in CN
Renal Anemia
Filed in ID
KRN1493
Cinacalcet
Hydrochloride
Oral
Calcium Receptor
Agonist
Secondary
Hyperparathyroidism
Immunology
/Allergy
AMG531
Romiplostim
Injection
Thrombopoietin
Receptor Agonist
Kirin-Amgen
Idiopathic (Immune)
Thrombocytopenic
Purpura
Phase III in CN
Other
New Molecular Entity
Asthma
Filed in JP
In-House
POTELLIGENT

Jointly Developed with
AstraZeneca/MedImmune
NDA holder is AstraZeneca
KHK4827
Brodalumab
Injection
Anti-IL-17 Receptor
A Fully Human
Antibody
Psoriasis
Filed in TW
Kirin-Amgen
◎KHK4563
Benralizumab
Injection
Anti-IL-5 Receptor
Humanized Antibody
antibody
protein
small molecule
Ｐ
h
I
As of Mar.31, 2017
Combination with
Durvalumab/Tremelimumab
(Jointly Developed with AstraZeneca)
Combination with Docetaxel
Combination with
PF-05082566
(Jointly Developed with Pfizer)
Phase I/II
in US
Combination with Nivolumab
(Jointly Developed with Bristol-Myers
Squibb)
PhaseI
in JP
Combination with Nivolumab
(Jointly Developed with
Ono Pharmaceutical)
◎KHK4083
Injection
Anti-OX40 Fully
Human Antibody
Ulcerative colitis
Phase Iin JP
In-House
◎KHK4083
Injection
Anti-OX40 Fully
Human Antibody
Ulcerative colitis
Phase Iin JP
In-House
PhaseIin EU
PhaseIin JP
Updated since Jan 24th,
2017 （Area, Stage, Filed, Approved, etc.）
◎
Updated since Jan 24th,
2017 （Area, Stage, Filed, Approved, etc.）
Filed・Approved
Nephrology
KRN321
Darbepoetin Alfa
Injection
Long-Acting
Erythropoiesis
Stimulating Agent
Myelodysplastic Syndromes Approved in SG Kirin-Amgen
R&D Pipeline
Other
Kirin-Amgen
In-House
or
Licensed
Remarks
Area
Code Name
Generic Name
Formulation
Mechanism of Action
Indication
Stage
KHK4827
Brodalumab
Injection
Anti-IL-17 Receptor
A Fully Human
Antibody
Psoriasis
Filed in TW
AMG531
Romiplostim
Injection
Thrombopoietin
Receptor Agonist
Idiopathic (Immune)
Thrombocytopenic
Purpura
Approved in TH
Immunology
/Allergy
In-House
POTELLIGENT

Jointly Developed with
AstraZeneca/MedImmune
NDA holder is AstraZeneca
◎KHK4563
Benralizumab
Injection
Anti-IL-5 Receptor
Humanized Antibody
Asthma
Filed in JP
Kirin-Amgen
In-House
Others
KW-3357
Antithrombin
Gamma
Injection
Recombinant Human
Antithrombin
Disseminated Intravascular
Coagulation, Congenital
Antithrombin Deficiency
Phase Iin EU
Licensed from
Immunas
Pharma
Immunology/
Allergy
POTELLIGENT

Human Antibody-Producing Technology
POTELLIGENT

Human Antibody-Producing Technology
PhaseI
in US
Remarks
POTELLIGENT

Human Antibody-Producing Technology
KW-0761
Mogamulizumab
Injection
Anti-CCR4
Humanized Antibody
Solid Tumor
Phase I
in US
In-House
POTELLIGENT

◎KHK2823
Injection
Anti-CD123 Fully
Human Antibody
Cancer
Phase I
in UK
In-House
In-House
Combination with KW-0761
PhaseI
in JP
Syndax
領域
Code Name
Generic Name
Formulation
Mechanism of Action
Indication
Stage
In-House
or
Licensed
◎KHK2455
Oral
IDO 1 Inhibitor
Solid Tumor
New Molecular Entity
Oncology
◎KHK2375
Entinostat
Oral
HDAC Inhibitor
Breast Cancer
Central
Nervous
System
◎KHK6640
Injection
Anti–Amyloid Beta
Peptide Antibody
Alzheimer’s Disease
antibody
protein
small molecule